These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
35. Neurofilament light is a treatment-responsive biomarker in CLN2 disease. Ru Y; Corado C; Soon RK; Melton AC; Harris A; Yu GK; Pryer N; Sinclair JR; Katz ML; Ajayi T; Jacoby D; Russell CB; Chandriani S Ann Clin Transl Neurol; 2019 Dec; 6(12):2437-2447. PubMed ID: 31814335 [TBL] [Abstract][Full Text] [Related]
36. First in man study of intravitreal tripeptidyl peptidase 1 for CLN2 retinopathy. Wawrzynski J; Martinez AR; Thompson DA; Ram D; Bowman R; Whiteley R; Gan C; Harding L; Mortensen A; Mills P; Gissen P; Henderson RH Eye (Lond); 2024 Apr; 38(6):1176-1182. PubMed ID: 38049626 [TBL] [Abstract][Full Text] [Related]
37. Intrathecal enzyme replacement therapy improves motor function and survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis. Lu JY; Nelvagal HR; Wang L; Birnbaum SG; Cooper JD; Hofmann SL Mol Genet Metab; 2015; 116(1-2):98-105. PubMed ID: 25982063 [TBL] [Abstract][Full Text] [Related]
38. Extraneuronal pathology in a canine model of CLN2 neuronal ceroid lipofuscinosis after intracerebroventricular gene therapy that delays neurological disease progression. Katz ML; Johnson GC; Leach SB; Williamson BG; Coates JR; Whiting REH; Vansteenkiste DP; Whitney MS Gene Ther; 2017 Apr; 24(4):215-223. PubMed ID: 28079862 [TBL] [Abstract][Full Text] [Related]
39. Managing CLN2 disease: a treatable neurodegenerative condition among other treatable early childhood epilepsies. Mazurkiewicz-Bełdzińska M; Del Toro M; Haliloğlu G; Huidekoper HH; Kravljanac R; Mühlhausen C; Andersen BN; Prpić I; Striano P; Auvin S Expert Rev Neurother; 2021 Nov; 21(11):1275-1282. PubMed ID: 33538188 [TBL] [Abstract][Full Text] [Related]